Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian NGO Challenges Patent For Roche’s Anti-HIV Valcyte

This article was originally published in PharmAsia News

Executive Summary

An Indian group has filed a challenge to the government's grant of a patent for Roche's Valcyte (valglanciclovir) drug for treating HIV. Roche received the patent last year from the Chennai patent office, but the challenge by the Delhi Network of Positive People said it was granted without hearing opposing arguments by two non-governmental organizations. The contention of the opposition is that the drug is a known compound, or at least no more than a new version of a known substance, and therefore does not justify a patent. Roche also holds patents on the drug in other countries. (Click here for more

You may also be interested in...

A Closer Look: India Patent Disputes Heat Up For Big Pharma

MUMBAI - Multinational pharmaceutical companies eyeing the growing Indian market may find themselves confronting a challenging patent environment during the next few years as public interest groups look to further intensify patent oppositions

What To Consider For German Orphan Drug Price Negotiations

The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.

Viatris’ UpJohn Breaking Taboo Around Erectile Dysfunction With UK PR Campaign

Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts